Welcome

Please select your view



Register now

Forgot login details?

comprehensivejpg

Comprehensive Somatic Mutation Testing

Comprehensive Oncomine Precision Assay (OPA) Gene Panel (ThermoFisher Scientific)

Local and International Guidelines (NCCN & ASCO) strongly recommend comprehensive multi-gene panel– based genomic sequencing for cancer patients with the goal of identifying rare driver mutations for which effective drugs may already be available. Comprehensive tumour profiling aids clinicians in selecting the most appropriate treatment for their cancer patients, avoiding unnecessary toxic therapy, resistance, or overtreatment, or in suggesting potential synergistic drug combinations (e.g., combination of BRAF and MEK inhibitors in BRAF mutant melanoma)1. This approach is also of valuable use if the tumour his poorly differentiated or of unknown origin.

Genes sequenced in this panel include:

AKT1 CHEK2 FGFR3 KIT NTRK3
AKT2 CTNNB1 FGFR4 KRAS PDGFRA
AKT3 EGFR FLT3 MAP2K1 PIK3CA
ALK ERBB2 GNA11 MAP2K2 PTEN
AR ERBB3 GNAQ MET RAF1
ARAF ERBB4 GNAS MTOR RET
BRAF ESR1 HRAS NRAS ROS1
CDK4 FGFR1 IDH1 NTRK1 SMO
CDKN2A FGFR2 IDH2 NTRK2 TP53

Comprehensive Oncomine Precision Assay (OPA) Gene Panel (Thermo Fisher Scientific)

When to Order: Comprehensive Diagnostic Protocol for Solid Tissue Cancers.
How to Order: Fill out our Somatic Mutation testing request form and tick the Somatic Mutation test panels required.
Turnaround Time: 5-7 business days after the receipt of the sample.
Specimen Required: Fresh formalin-fixed paraffin-embedded (FFPE) of 5-10 μm thickness from the tumour tissue. 
Test Cost: The Comprehensive Tumour Somatic Mutation Panel is Non-Medicare rebatable. An out-of-pocket fee of $750 applies.

References
1. Malone E et al., Genome Medicine (2020). Molecular profiling for precision cancer therapies 12:8. 


Download Somatic Mutation Brochure

Download Somatic Mutation Request Form Download Somatic Mutation Request Form - WA


The content on our Molecular Cancer Services page is written by Associate Professor Mirette Saad, National Director of Molecular Genetics at Australian Clinical Labs. 

 

Assoc. Prof. Mirette Saad

MBBS (Hons), MD, MAACB, FRCPA, PhD
Lab: Clayton
Speciality: Chemical Pathology and Molecular Genetics
Areas Of Interest: Cancer Genetics, Antenatal Screening, NIPT, Endocrine, Fertility Testing and Research, Medical Teaching
Phone: 1300 134 111
Email: mirette.saad@clinicallabs.com.au

Associate Professor Mirette Saad is a Consultant Chemical Pathologist and the National Director of Molecular Genetics at Australian Clinical Labs. She has a Fellowship with honours in Chemical and Molecular Pathology, with Microbiology sub-speciality, from Suez Canal University, Egypt. A/P Saad received her NHMRC sponsored PhD degree in Cancer Genetics from Melbourne University and Peter MacCallum Cancer Institute. Along with her teaching and research roles, A/P Saad is a registered medical practitioner with AHPRA, a Chemical Pathology Fellow (FRCPA) at the Royal College of Pathologists of Australasia and a Member of the Australasian Association of Clinical Biochemists (MAACB). She is a Chair of the RCPA Chemical Pathology Advisory Committee, Member of the RCPA Genetic Advisory Committee, AACB and a Chair of the Precision Medicine Services at Australian Clinical Labs. At Clinical Labs, A/Prof Mirette Saad leads the Molecular Genetic testing for non-invasive prenatal testing (NIPT), antenatal screening, personalised drug therapy and cancer.

Back to Molecular Cancer Services Homepage

Related Articles